查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835283

人體肝臟模型市場（按模型類型、細胞來源、應用和最終用戶）—2025-2032 年全球預測

Human Liver Model Market by Model Type, Cell Source, Application, End Users - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人體肝臟模型市場將成長 30.5 億美元，複合年成長率為 8.75%。

主要市場統計數據
基準年2024年 15.5億美元
預計2025年 16.8億美元
預測年份：2032年 30.5億美元
複合年成長率（%） 8.75%

技術整合和實踐檢驗的整體情況將決定人類肝臟模型未來的效用和操作應用

人體肝臟模型的演變代表著生物學、工程學和計算科學的融合，重塑了學術界和產業界以肝臟為重點的研發方式。支架設計、微生理系統、幹細胞分化方案和多組體學讀數的進步提高了生理相關性，並使藥物代謝、肝毒性和疾病建模的研究更具預測性。這些技術改進正被應用於從早期標靶檢驗到後期轉化研究的各種工作流程，迫使研究機構重新思考實驗設計和資源分配。

重要的是，疫情期間遠端協作和數位數位資料整合的加速，擴大了對In Silico方法的需求，以補充濕實驗室模型，從而創建將2D平台、3D結構與計算模擬相結合的混合工作流程。因此，相關人員更加重視模型的可重複性、標準化以及與高內涵讀數的兼容性。因此，優先考慮跨學科驗證和可擴展製造實踐的組織將更有能力將模型改進轉化為可重複且符合法規要求的結果。

展望未來，人體肝臟模型的常規應用正從概念驗證轉向實際操作和資格確認階段。這項轉變需要在品管、檢測方法協調以及臨床和臨床前終點的透明基準測試方面進行策略性投資，從而為其在藥物安全、疾病研究和教育領域的更廣泛效用奠定基礎。

突破性工程、品質主導的商業化和協作標準化如何重塑先進人體肝臟模型的接受度和用例

由於科學突破和相關人員期望的轉變，人類肝臟模型的格局正在發生重大變化。細胞獲取、微流體整合和資料讀取方面的進步，已將微生理系統和肝臟類器官從單一的研究工具轉變為為藥物研發和安全評估提供決策依據的平台。這種轉變正在促進跨學科夥伴關係，將組織工程與計算預測相結合，從而產生更豐富的多模態資料集，以支援機制研究。

同時，最終用戶對可重複性和通量的要求也越來越高，這推動了製造、自動化和品管領域的創新。受託研究機構和生物技術公司擴大提供承包模型解決方案，降低了需要穩健、可擴展方案的製藥項目和學術實驗室的准入門檻。同時，學術團體繼續專注於疾病特異性建模，特別是代謝性和纖維化肝病，從而拓展了肝臟模型至關重要的生物學應用範圍。

這些發展也推動了跨部門合作的新形式，包括與監管機構進行試點資格確認研究、建立競爭前聯盟以製定基準化分析標準，以及官民合作關係以加速轉化進程。總而言之，這些轉變正在重新定義人們對經過驗證、可立即用於決策的肝臟模型的期望。

分析 2025 年關稅趨勢的變化如何推動模型開發商的策略供應鏈多樣化、本地化和採購彈性

2025年的關稅政策和貿易動態為在國際範圍內採購材料、設備和模型系統的組織帶來了新的策略考量。為了應對這些關稅帶來的成本壓力，許多供應商和最終用戶正在重新評估其供應鏈佈局和籌資策略，以保持其科學研究營運的連續性。這加速了人們對關鍵零件（例如微流體晶片、細胞外基質材料以及支援可重複肝臟模型生成的標準化耗材）的本地製造能力的興趣。

因此，相關人員優先考慮供應鏈的韌性，透過提高透明度並透過供應商多元化和更緊密的供應商關係提供應急計畫。同時，各組織正在評估垂直整合某些功能（例如細胞衍生、品管和檢測自動化）與依賴外部服務提供者的成本效益。這些策略舉措正在與保持地理集中度以及維持對專業知識和創新中心的存取權的需求之間取得平衡。

因此，關稅環境促使人們更廣泛地重新思考採購、製造規模和夥伴關係模式，凸顯了適應性籌資策略、本地製造投資以及減輕地緣政治和監管風險的合約機制的重要性。

細分情報揭示了模型類型、細胞來源、應用重點和最終用戶優先級如何決定採用路徑和商業化策略

細緻的細分視角揭示了不同模型類型、細胞來源、應用程式和最終用戶類別中不同的應用促進因素和業務需求。模型類型涵蓋傳統的2D模型、新興的3D模型、體外構建體、In Silico模擬和肝臟器官，每種模型在生理相關性、擴充性和整合複雜性之間都有其獨特的權衡。優先考慮高篩檢的架構通常會保留2D平台以實現成本效益和簡便性，而專注於轉化保真度的項目則擴大投資於3D構建體和類器官，以捕捉多細胞結構和功能終點。

從永生化細胞株和原代人類肝細胞到幹細胞衍生模型，細胞來源的選擇會影響實驗設計和後續結果解讀。原代細胞具有與臨床相似的表現型，但在供應和變異性方面存在挑戰。另一方面，幹細胞衍生方法為疾病建模提供了擴充性和靈活性。永生化細胞係對於機制闡明和檢測方法開發仍然效用，尤其是與基因編輯和標準化讀數相結合時。在藥物研發中，平衡通量和預測值至關重要，而生理學和毒理學研究等教育目的則優先考慮可重複性和成本效益，以支持課程和培訓目標。

生物技術和製藥公司專注於轉化驗證及其與前臨床開發平臺的整合，企業合約研究組織專注於服務擴充性和法規合規性，研究實驗室則專注於實驗靈活性和新穎的假設檢驗。了解模型類型、細胞來源、應用和最終用戶優先順序之間的相互關係，對於設計滿足不同相關人員需求的商業化方法、夥伴關係和檢驗研究至關重要。

美洲、歐洲、中東和非洲以及亞太地區的戰略對比和能力將決定招聘軌跡和夥伴關係機會

美洲、歐洲、中東和非洲以及亞太地區的區域動態將對應用程式時程、商業化策略和夥伴關係模式產生重大影響。美洲地區擁有強大的轉化生態系統，且接近性主要製藥中心，這有利於早期採用高保真度3D系統和類器官，並專注於將模型整合到安全性和代謝工作流程中。該地區的資金籌措格局和創投活動也青睞那些能夠證明符合監管環境並具備可擴展製造能力的新興企業。

歐洲、中東和非洲 歐洲、中東和非洲展現出多元化的學術成就、監管參與和產業合作，促進了嚴格的檢驗工作和競爭前聯盟的形成。該地區通常在為複雜的組織模式建立跨學科標準和倫理框架方面發揮主導作用，從而開闢了獲得資格的途徑。相較之下，亞太地區以快速的生產規模擴大、具有成本競爭力的服務交付以及對生物技術基礎設施的策略性公共投資而聞名，使其成為本地生產、大規模合約服務和臨床轉化舉措的關鍵地區。

針對每個地區制定量身定做的策略至關重要，要認知到監管互動、資金籌措機制和製造能力的差異。合作夥伴和投資者需要製定產業計畫，充分利用當地優勢，利用當地人才庫和基礎設施，同時滿足全球認證和品質要求。

對競爭格局、夥伴關係模式和驗證主導的差異化策略的考慮將決定人類肝臟模型領域的潛在領導地位

現有企業、專業新興企業和服務供應商之間的競爭動態，由平台工程、細胞採購、檢測方法開發和監管參與的互補優勢所塑造。領先的學術衍生公司和生物技術公司憑藉專有的差異化方案、微加工專業知識和整合分析工具鏈脫穎而出，為最終用戶提供可靠的測量結果。同時，合約委外研發機構和平台提供者擴大建立策略夥伴關係，提供滿足端到端需求的配套服務，從模型資格確認和檢測方法驗證到符合GLP（良好實驗室規範）的資料收集。

平台開發商和製藥團隊之間的合作日益頻繁，他們透過簽訂共同開發契約和中試資格確認研究來降低藥物開發平臺的整合風險。此外，人們對授權協議和策略投資的興趣日益濃厚，以加速規模化和市場准入，尤其是在共享能夠證明轉化一致性的驗證資料集方面。對於尋求競爭的公司而言，成功取決於清晰的價值主張、檢驗的效能聲明以及可證明的營運擴充性，以支援多樣化的客戶工作流程。

投資者和企業開發團隊應密切追蹤夥伴關係、技術轉移協議和平台互通性舉措，因為這些活動通常預示著更廣泛的商業性應用，並基於數據生態系統和檢驗端點設置差異化障礙。

為領導者提供實際的優先行動，以標準化檢驗、擴大生產規模、建立策略合作夥伴關係，並使商業模式與最終用戶需求保持一致

產業領導者應採取積極主動的方法，在科學嚴謹性、營運擴充性和商業性誠信之間取得平衡。首先，優先考慮標準化驗證框架，該框架將模型輸出映射到臨床相關的生物標記物，並為整合到藥物發現和安全工作流程中提供清晰的決策閘。同時，投資擴充性的生產和品質體系，以減少合作夥伴和客戶的差異性，並縮短資格確認時間。儘早與監管相關人員溝通並參與跨部門基準化分析舉措，可以加快產品被接受的速度並降低轉換風險。

其次，尋求能夠補充您內部能力的策略夥伴關係。例如，與計算生物學團隊合作進行In Silico整合，與細胞療法創新者合作以增強細胞採購，並與合約研究公司合作提供服務以擴大您的業務範圍。第三，透過提供靈活的商業模式（例如基於訂閱的存取、試點資格套餐以及針對學術計畫的教育許可），使您的市場進入策略與最終用戶需求保持一致。最後，透過考慮區域製造、多供應商協議和庫存對沖來保持靈活的籌資策略，以避免地緣政治和關稅壓力並保持業務連續性。

透過應對這些挑戰，公司可以加快模型認證，擴大市場進入，並基於檢驗的性能和以客戶為中心的交付建立穩固的地位。

採用嚴格的混合方法，結合主要專家訪談、技術文獻綜合和迭代檢驗，確保了可操作且可靠的研究結果

本執行摘要所依據的研究結合了與領域專家的結構化一手訪談，以及對同行評審文獻、技術白皮書、監管指南和公司披露資訊的二次綜合。關鍵的定性資訊包括與平台開發者、細胞採購專家、製藥公司和合約研發的最終用戶，以及在疾病相關環境中應用模型的轉化科學家的訪談。這些對話提供了關於營運挑戰、檢驗重點以及商業性化應用促進因素的詳細見解。

我們的二次分析系統地回顧了組織工程、幹細胞分化方案、微流體和計算建模方面的方法學進展，並結合近期臨床前和轉化研究的調查，對模型性能進行了基準測試。我們也透過專家檢驗會議反覆完善研究結果，以確保技術準確性和實務相關性。我們也考慮了倫理考量、生產限制以及與監管機構的溝通，以提供平衡的觀點來支持策略決策。

這種混合方法確保結論既反映當前的科學進步狀況，也反映開發人員、最終用戶和投資者面臨的營運現實。

營運準備、檢驗嚴謹性和策略一致性將決定誰將主導將模型進步轉化為實際研究和商業性價值。

總而言之，在技術融合、細胞採購改進以及對可重複性和監管相關性更高期望的推動下，人類肝臟模型生態系統正從探索性創新走向成熟，邁向營運就緒。投資於穩健驗證、可擴展生產和策略夥伴關係關係的相關人員將最有能力將模型效能轉化為實際的研究和商業性成果。同時，地緣政治和關稅因素正在重塑供應鏈策略，凸顯了對在地化能力和多元化採購的需求。

這意味著要優先考慮濕實驗室和In Silico方法之間的互通性，積極與監管機構和聯盟合作制定驗收標準，並設計符合最終用戶工作流程的商業產品。透過這樣做，組織不僅可以提高實驗的可預測性，還可以在藥物研發、毒理學教育和疾病建模等領域開闢新的應用，從而提昇科學價值和商業性價值。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 3D生物列印人體肝組織在高通量藥物肝毒性篩檢的應用日益廣泛
  • 將微流體肝臟晶片平台與多器官系統結合，實現全面的藥物動力學建模
  • iPSC 衍生的肝類器官的興起使得創建患者特異性疾病模型和個人化治療發現成為可能
  • 生物技術公司與學術中心建立策略夥伴關係關係，擴大標準化人體肝臟模型生產
  • 監管參與和標準化努力，推動體外人體肝臟模型在醫藥品認證過程中的接受

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 人體肝臟模型市場（依模型類型）

  • 2D模型
  • 3D模型
  • 體外模型
  • In Silico模型
  • 肝臟類器官

9. 人體肝臟模型市場（依細胞來源）

  • 永生化肝細胞株
  • 原代人類肝細胞
  • 幹細胞衍生模型

第10章人體肝臟模型市場（依應用）

  • 藥物研發
  • 教育
    • 生理研究
    • 毒理學研究

第 11 章人體肝臟模型市場（依最終用戶分類）

  • 生技公司
  • 合約研究組織
  • 製藥公司
  • 實驗室

12. 人體肝臟模型市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章人體肝臟模型市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國人體肝臟模型市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Ascendance Bio
    • BioIVT LLC
    • Cellink Global by BICO Group AB
    • CN Bio Innovations Ltd.
    • Corning Incorporated
    • Cyfuse Biomedical KK
    • EISCO Scientific LLC
    • Emulate Inc.
    • Hurel Corporation
    • InSphero AG
    • Kirkstall Ltd
    • MIMETAS BV
    • NeurOmics, Inc.
    • Organovo Holdings Inc.
    • Pandorum Technologies Private Limited
    • PhoenixBio Co., Ltd.
    • STEMCELL Technologies Inc.
Product Code: MRR-43127F7278DC

The Human Liver Model Market is projected to grow by USD 3.05 billion at a CAGR of 8.75% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.55 billion
Estimated Year [2025] USD 1.68 billion
Forecast Year [2032] USD 3.05 billion
CAGR (%) 8.75%

A panoramic overview of technological integration and practical validation shaping the future utility and operational adoption of human liver models

The evolution of human liver models represents a convergence of biology, engineering, and computational sciences that is reshaping how industry and academia approach liver-focused research and development. Advances in scaffold design, microphysiological systems, stem cell differentiation protocols, and multi-omics readouts have collectively improved physiological relevance, enabling more predictive interrogation of drug metabolism, hepatotoxicity, and disease modeling. These technological improvements are being adopted across diverse workflows, from early-stage target validation to later-stage translational research, which is prompting institutions to reassess experimental design and resource allocation.

Importantly, the pandemic-era acceleration of remote collaboration and digital data integration has amplified demand for in silico approaches that complement wet-lab models, thereby creating hybrid workflows that combine 2D platforms and 3D constructs with computational simulations. As a result, stakeholders are placing greater emphasis on model reproducibility, standardization, and compatibility with high-content readouts. Consequently, organizations that prioritize cross-disciplinary validation and scalable manufacturing practices will be better positioned to translate model improvements into reproducible, regulatory-relevant outcomes.

Looking ahead, the narrative is shifting from proof-of-concept demonstrations to operationalization and qualification of human liver models for routine use. This transition demands strategic investments in quality management, assay harmonization, and transparent benchmarking against clinical and preclinical endpoints, establishing a foundation for broader utility in drug safety, disease research, and education.

How breakthrough engineering, quality-driven commercialization, and collaborative standards are reconfiguring acceptance and use cases for advanced human liver models

The landscape for human liver models is undergoing transformative shifts driven by a combination of scientific breakthroughs and changing stakeholder expectations. Microphysiological systems and liver organoids are moving from niche research tools to platforms that can inform decision-making across drug discovery and safety assessment, driven by improvements in cellular sourcing, microfluidic integration, and readout sophistication. This shift is encouraging multidisciplinary partnerships that marry tissue engineering with computational prediction, thereby enabling richer, multi-modal datasets that support mechanistic insights.

Simultaneously, end users are demanding higher standards for reproducibility and throughput, prompting innovations in manufacturing, automation, and quality control. Contract research organizations and biotech companies are increasingly offering turnkey model solutions, lowering barriers to adoption for pharmaceutical programs and academic labs that need robust, scalable options. In parallel, academic groups continue to push the envelope on disease-specific modeling, particularly for metabolic and fibrotic liver conditions, which is expanding the biological contexts in which liver models are considered indispensable.

These developments are also prompting new modalities of collaboration across sectors, including pilot qualification studies with regulators, pre-competitive consortia to define benchmarking standards, and private-public partnerships that accelerate translational pathways. Collectively, these shifts are redefining expectations for what constitutes a validated, decision-grade liver model.

Analyzing how evolving tariff dynamics in 2025 are prompting strategic supply chain diversification, localized manufacturing, and procurement resilience for model developers

Tariff policies and trade dynamics in 2025 have introduced a new set of strategic considerations for organizations that source materials, equipment, and model systems internationally. In response to these tariff-induced cost pressures, many suppliers and end users are reevaluating supply chain footprints and sourcing strategies to maintain continuity of scientific operations. This has accelerated interest in regional manufacturing capabilities for critical components such as microfluidic chips, extracellular matrix materials, and standardized consumables that support reproducible liver model production.

As a result, stakeholders are increasingly prioritizing supply chain resilience through diversification of vendors and closer supplier relationships that offer greater transparency and contingency planning. At the same time, organizations are assessing the cost-benefit of vertically integrating certain capabilities-such as cell derivation, quality control, and assay automation-versus relying on external service providers. These strategic moves are being balanced with the need to preserve access to specialized expertise and innovation hubs that remain geographically concentrated.

Consequently, the tariff environment has catalyzed a broader rethinking of procurement, manufacturing scale, and partnership models, underlining the importance of adaptive sourcing strategies, localized production investments, and contractual mechanisms that mitigate geopolitical and regulatory risk.

Segment-level intelligence revealing how model type, cell source, application focus, and end-user priorities determine adoption pathways and commercialization strategies

A nuanced view of segmentation reveals differentiated adoption drivers and operational imperatives across model type, cell source, application, and end-user categories. Model types span traditional 2D models and emerging 3D models, Ex Vivo constructs, In Silico simulations, and Liver Organoids, each offering unique trade-offs between physiological relevance, scalability, and integration complexity. Organizations that prioritize high-throughput screening often retain 2D platforms for their cost-effectiveness and simplicity, while programs focused on translational fidelity are increasingly investing in 3D constructs and organoids to capture multicellular architecture and functional metrics.

Cell source decisions-ranging from Immortalized Liver Cell Lines and Primary Human Hepatocytes to Stem Cell-Derived Models-inform both experimental design and downstream interpretation. Primary cells offer clinically proximal phenotypes but present supply and variability challenges, whereas stem cell-derived approaches provide scalability and disease modeling flexibility. Immortalized lines maintain utility for mechanistic probing and assay development, especially when combined with genetic editing and standardized readouts. These choices cascade into application-specific strategies: drug discovery initiatives balance throughput and predictive value, while educational uses, including physiological and toxicology studies, emphasize reproducibility and cost-efficiency to support curriculum and training objectives.

End-user profiles further shape technology adoption pathways, with Biotech Companies and Pharmaceutical Companies focusing on translational validation and integration with preclinical pipelines, Contract Research Organizations centering on service scalability and regulatory alignment, and Research Laboratories prioritizing experimental flexibility and novel hypothesis testing. Understanding how model type, cell source, application, and end-user priorities interrelate is critical for designing commercialization approaches, partnerships, and validation studies that meet diverse stakeholder needs.

Regional strategic contrasts and capabilities across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption trajectories and partnership opportunities

Regional dynamics materially influence adoption timelines, commercialization strategies, and partnership models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, strong translational ecosystems and proximity to major pharmaceutical hubs support early adoption of higher-fidelity 3D systems and organoids, with an emphasis on integrating models into safety and metabolism workflows. Funding landscapes and venture activity in this region also favor startups that can demonstrate regulatory alignment and scalable manufacturing.

Europe, Middle East & Africa exhibit a diverse mosaic of academic excellence, regulatory engagement, and industrial collaboration that fosters rigorous validation efforts and pre-competitive consortia. This region often leads in establishing interdisciplinary standards and ethical frameworks for complex tissue models, which in turn informs qualification pathways. In contrast, the Asia-Pacific region is notable for rapid manufacturing scale-up, cost-competitive service provision, and strategic public investment in biotechnology infrastructure, making it a pivotal zone for localized production, large-scale contract services, and clinical translation initiatives.

A regionally attuned strategy that recognizes differences in regulatory dialogue, funding mechanisms, and manufacturing capacities will be essential. Partners and investors should align operational plans with regional strengths, leveraging local talent pools and infrastructure while ensuring harmonization with global validation and quality expectations.

Insight into competitive positioning, partnership models, and validation-driven differentiation strategies that dictate leadership potential in the human liver model landscape

Competitive dynamics among established firms, specialized startups, and service providers are shaped by complementary strengths in platform engineering, cell sourcing, assay development, and regulatory engagement. Leading academic spinouts and biotech companies often differentiate through proprietary differentiation protocols, microfabrication expertise, and integrated analytical toolchains that provide end users with higher-confidence readouts. At the same time, contract research organizations and platform providers are increasingly forming strategic partnerships to offer bundled services that address end-to-end needs-from model qualification and assay validation to GLP-compatible data capture.

Collaboration between platform developers and pharmaceutical teams is becoming more frequent, with co-development agreements and pilot qualification studies used to de-risk integration into drug development pipelines. Additionally, there is growing interest in licensing arrangements and strategic investments that accelerate scale-up and market reach, especially when combined with shared validation datasets that demonstrate translational concordance. For companies seeking to compete, success depends on clear value articulation, validated performance claims, and demonstrable operational scalability to support diverse customer workflows.

Investors and corporate development teams should track partnerships, technology transfer agreements, and platform interoperability initiatives closely, as these activities often presage broader commercial uptake and create differentiation barriers based on data ecosystems and validated endpoints.

Practical, prioritized actions for leaders to standardize validation, scale manufacturing, form strategic alliances, and align commercial models with end-user needs

Industry leaders should adopt a proactive approach that balances scientific rigor, operational scalability, and commercial alignment. First, prioritize standardized validation frameworks that map model outputs to clinically relevant biomarkers, enabling clearer decision gates for integration into drug discovery and safety workflows. Concurrently, invest in scalable manufacturing and quality systems to reduce variability and shorten qualification timelines for partners and customers. Early engagement with regulatory stakeholders and participation in cross-sector benchmarking initiatives will accelerate acceptance and reduce translational risk.

Second, pursue strategic partnerships that complement internal capabilities-such as collaborations with computational biology groups for in silico integration, alliances with cell therapy innovators for enhanced cell sourcing, and service partnerships with contract research providers to expand reach. Third, tailor go-to-market strategies to end-user needs by offering flexible commercial models that include subscription-based access, pilot qualification packages, and educational licensing for academic programs. Finally, maintain an adaptive sourcing strategy to navigate geopolitical and tariff pressures by exploring regional manufacturing, multi-supplier agreements, and inventory hedging that preserve operational continuity.

By executing on these fronts, organizations can accelerate model qualification, broaden market access, and establish defensible positions grounded in validated performance and customer-centric delivery.

A rigorous mixed-methods approach combining primary expert interviews, technical literature synthesis, and iterative validation to ensure actionable and credible findings

The research underpinning this executive summary combined structured primary engagement with subject-matter experts and secondary synthesis of peer-reviewed literature, technical whitepapers, regulatory guidance, and company disclosures. Key qualitative inputs included interviews with platform developers, cell sourcing specialists, end users in pharmaceutical and contract research settings, and translational scientists who apply models in disease-relevant contexts. These conversations provided granular insights into operational challenges, validation priorities, and commercial adoption drivers.

Secondary analysis involved systematic review of methodological advancements in tissue engineering, stem cell differentiation protocols, microfluidics, and computational modeling, supplemented by examination of recent preclinical and translational studies that benchmark model performance. Data triangulation was used to cross-validate thematic findings across sources, and findings were iteratively refined through expert validation sessions to ensure technical accuracy and practical relevance. Ethical considerations, manufacturing constraints, and regulatory dialogue were also incorporated to present a balanced view that supports strategic decision-making.

This mixed-methods approach ensures that conclusions reflect both the current state of scientific advancement and the operational realities facing developers, end users, and investors.

Key takeaways emphasizing operational readiness, validation rigor, and strategic alignment that will determine who leads in translating model advancements into practical research and commercial value

In conclusion, the human liver model ecosystem is maturing from exploratory innovation toward operational readiness, driven by technological convergence, improved cellular sourcing, and higher expectations for reproducibility and regulatory relevance. Stakeholders who invest in robust validation, scalable manufacturing, and strategic partnerships will be best positioned to translate model performance into tangible research and commercial outcomes. At the same time, geopolitical and tariff considerations are reshaping supply chain strategies, highlighting the need for localized capabilities and diversified sourcing.

The implications for industry participants are clear: prioritize interoperability between wet-lab and in silico approaches, engage proactively with regulators and consortia to define acceptance criteria, and design commercial offerings that map to end-user workflows. By doing so, organizations can not only improve experimental predictability but also unlock new applications in drug discovery, toxicology education, and disease modeling that together advance both science and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of 3D bioprinted human liver tissues for high throughput drug hepatotoxicity screening
  • 5.2. Integration of microfluidic liver on chip platforms with multi organ systems for holistic pharmacokinetic modeling
  • 5.3. Rise of iPSC derived liver organoids enabling patient specific disease modeling and personalized therapeutic discovery
  • 5.4. Strategic partnerships between biotech firms and academic centers to scale standardized human liver model production
  • 5.5. Regulatory engagement and standardization efforts for acceptance of in vitro human liver models in drug approval process

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Liver Model Market, by Model Type

  • 8.1. 2D Models
  • 8.2. 3D Models
  • 8.3. Ex Vivo Models
  • 8.4. In Silico Models
  • 8.5. Liver Organoids

9. Human Liver Model Market, by Cell Source

  • 9.1. Immortalized Liver Cell Lines
  • 9.2. Primary Human Hepatocytes
  • 9.3. Stem Cell-Derived Models

10. Human Liver Model Market, by Application

  • 10.1. Drug Discovery
  • 10.2. Education
    • 10.2.1. Physiological Studies
    • 10.2.2. Toxicology Studies

11. Human Liver Model Market, by End Users

  • 11.1. Biotech Companies
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical Companies
  • 11.4. Research Laboratories

12. Human Liver Model Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Human Liver Model Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Liver Model Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Ascendance Bio
    • 15.3.2. BioIVT LLC
    • 15.3.3. Cellink Global by BICO Group AB
    • 15.3.4. CN Bio Innovations Ltd.
    • 15.3.5. Corning Incorporated
    • 15.3.6. Cyfuse Biomedical K.K.
    • 15.3.7. EISCO Scientific LLC
    • 15.3.8. Emulate Inc.
    • 15.3.9. Hurel Corporation
    • 15.3.10. InSphero AG
    • 15.3.11. Kirkstall Ltd
    • 15.3.12. MIMETAS B.V.
    • 15.3.13. NeurOmics, Inc.
    • 15.3.14. Organovo Holdings Inc.
    • 15.3.15. Pandorum Technologies Private Limited
    • 15.3.16. PhoenixBio Co., Ltd.
    • 15.3.17. STEMCELL Technologies Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN LIVER MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HUMAN LIVER MODEL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HUMAN LIVER MODEL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HUMAN LIVER MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HUMAN LIVER MODEL MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN LIVER MODEL MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 178. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 185. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 190. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 191. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 216. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 223. GCC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GCC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GCC HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. GCC HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. GCC HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 228. GCC HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 229. GCC HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. GCC HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. GCC HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 232. GCC HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 233. GCC HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 234. GCC HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 247. BRICS HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. BRICS HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. BRICS HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. BRICS HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. BRICS HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 252. BRICS HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 253. BRICS HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. BRICS HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 255. BRICS HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 256. BRICS HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 257. BRICS HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 258. BRICS HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 259. G7 HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. G7 HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. G7 HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. G7 HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. G7 HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 264. G7 HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 265. G7 HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. G7 HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. G7 HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 268. G7 HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 269. G7 HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 270. G7 HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 271. NATO HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NATO HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NATO HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. NATO HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. NATO HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 276. NATO HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 277. NATO HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. NATO HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. NATO HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 280. NATO HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 281. NATO HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 282. NATO HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 289. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 295. CANADA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. CANADA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. CANADA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 298. CANADA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 299. CANADA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 300. CANADA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 301. CANADA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 302. CANADA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 303. CANADA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 304. CANADA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 305. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 308. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 309. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 311. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 312. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 313. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 314. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 315. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 318. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 319. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 321. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 322. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 323. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 324. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 335. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 338. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 339. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 340. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 341. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 342. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 343. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 344. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 345. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. FRANCE HUMAN LIVER